Stock Suspensions/Halts Monday, September 16, 2013 3:20:47

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Stock Suspensions/Halts Monday, September 16, 2013 3:20:47 PM

Effective Date Symbol Company Name Security Type Venue Status
Sept 16, 2013 UERLF US Oil Sands, Inc. Ordinary Shares Grey Market Halted
Sept 16, 2013 TMGEF Thermal Energy International Inc. Ordinary Shares Grey Market Halted
Sept 16, 2013 SPIHF Sphere 3D Corp. Common Stock Grey Market Halted
Sept 16, 2013 NIVS NIVS IntelliMedia Technology Group, Inc. Common Stock OTC Link Revoked
Sept 16, 2013 NIVS NIVS IntelliMedia Technology Group, Inc. Common Stock OTC Link Halted
Sept 16, 2013 KLNDF Klondex Mines Ltd. Ordinary Shares OTC Link Halted
Sept 16, 2013 FPRGF Falco Pac Resource Group Inc  Grey Market Halted
Sept 16, 2013 CRTX Cornerstone Therapeutics, Inc. Common Stock Nasdaq Halted
Sept 16, 2013 CILE China Intelligent Lighting and Electronics, Inc. Common Stock Grey Market Revoked
Sept 13, 2013 SLAW St. Lawrence Energy Corp. Common Stock Grey Market Revoked
Sept 13, 2013 IVOI iVoice, Inc. Common Stock Grey Market Revoked
Sept 13, 2013 GYRO Gyrodyne Co. of America, Inc. Common Stock Nasdaq Halted
Sept 12, 2013 WLBR Wilson Brothers USA, Inc. Common Stock Grey Market Suspended
Sept 12, 2013 UPHN Uphonia, Inc. Common Stock Grey Market Suspended
Sept 12, 2013 SOBGF Soil Biogenics Ltd. Ordinary Shares Grey Market Revoked
Sept 12, 2013 PRBZF Premium Brands Holding Corp. Ordinary Shares Grey Market Halted
Sept 12, 2013 PCMEF Princeton Media Group, Inc. Ordinary Shares Grey Market Suspended
Sept 12, 2013 LRRS Laureate Resources & Steel Industries, Inc. Common Stock Grey Market Revoked
Sept 12, 2013 KNECQ Knight Energy Corp. Common Stock Grey Market Suspended
Sept 12, 2013 KMDO Komodo, Inc. Common Stock Grey Market Suspended
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading